A bioluminescent probe, BLGLN, comprising BL568 and ASCT2‐uptaken AA201, enables real‐time monitoring and evaluation of ASCT2‐mediated glutamine uptake rates in living tumors via Staudinger ligation, aiding tumor metabolism studies and targeted therapeutics. Here, SLC1A5 is linked to neoplasm.